readthroughSign in
Oct 2, 2026Weekly roundupUpdated

Amgen gets FDA biosimilar supplement approval for RIABNI; posts new evolocumab PK trial

Amgen's weekly filings include an FDA-approved RIABNI supplement, a completed evolocumab bioavailability study, a new kidney disease Phase 3, and two held-over trial statuses.

This week's Amgen activity centers on an FDA approval and a newly completed pharmacokinetic study, alongside continuing trials reported previously.

  • The FDA approved a supplement to Amgen's biologics license application for RIABNI, a rituximab-arrx injectable, under submission type "SUPPL" with a bioequivalence submission class. The approval letter is dated September 29, 2026, under application number BLA761140.1
  • Amgen completed a Phase 1 trial comparing two evolocumab (AMG 145) drug substance formulations in healthy volunteers. The study started April 21, 2026 and reached study completion September 8, 2026,2 with an enrollment of 405 participants2 measuring pharmacokinetic parameters including AUC and Cmax.
  • Amgen's new Phase 3 "MOMENT" trial (NCT07851220) is testing inebilizumab against tacrolimus in adults with primary membranous nephropathy, aiming to evaluate inebilizumab's effect on disease activity as measured by complete remission in participants with PMN3, with an estimated enrollment of 159 participants.
  • Amgen's Phase 3 pediatric psoriasis study of apremilast (AMG 407, Otezla) in Japanese participants ages 6 through 17 is listed as completed, with primary completion on November 20, 2025, and study completion on September 3, 20264, and enrollment of 21 participants.
  • Amgen's Phase 3 MARITIME-OSA-2 trial of maridebart cafraglutide versus placebo in adults with obstructive sleep apnea remains listed as active, not recruiting5, with an estimated enrollment of 250 participants.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.